An International Journal of Inorganic Chemistry Number 23 | 21 June 2008 | Pages 3017–3124

Total Page:16

File Type:pdf, Size:1020Kb

An International Journal of Inorganic Chemistry Number 23 | 21 June 2008 | Pages 3017–3124 An international journal of inorganic chemistry www.rsc.org/dalton Number 23 | 21 June 2008 | Pages 3017–3124 ISSN 1477-9226 COMMUNICATION COVER ARTICLE Wang et al. Lukes et al. A new heart-like Co-containing Gadolinium(III) complexes as MRI polyoxoanion based on the contrast agents lacunary Preyssler anion 1477-9226(2008)23;1-4 PERSPECTIVE www.rsc.org/dalton | Dalton Transactions Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes Petr Hermann, Jan Kotek, Vojtechˇ Kub´ıcekˇ and Ivan Lukes*ˇ Received 21st December 2007, Accepted 11th February 2008 First published as an Advance Article on the web 27th March 2008 DOI: 10.1039/b719704g Magnetic resonance imaging is a commonly used diagnostic method in medicinal practice as well as in biological and preclinical research. Contrast agents (CAs), which are often applied are mostly based on Gd(III) complexes. In this paper, the ligand types and structures of their complexes on one side and a set of the physico-chemical parameters governing properties of the CAs on the other side are discussed. The solid-state structures of lanthanide(III) complexes of open-chain and macrocyclic ligands and their structural features are compared. Examples of tuning of ligand structures to alter the relaxometric properties of gadolinium(III) complexes as a number of coordinated water molecules, their residence time (exchange rate) or reorientation time of the complexes are given. Influence of the structural changes of the ligands on thermodynamic stability and kinetic inertness/lability of their lanthanide(III) complexes is discussed. Introduction In the course of time, it was found that in some examinations of, e.g. the gastrointestinal tract (GIT) or cerebral area, the Tomography of magnetic resonance (Magnetic Resonance Imag- information obtained from a simple MRI image might not be ing, MRI) has gained great importance in the last three decades sufficient. In these cases, the administration of a suitable contrast- in medicinal diagnostics as an imaging technique with a superior enhancing agent (CA) proved to be extremely useful. Quite soon, 1 spatial resolution and contrast. The most important advantage of it was demonstrated that the most promising class of CAs could MRI over the competing radio-diagnostic methods such as X-Ray be compounds comprising paramagnetic metal ions. The first Computer Tomography (CT), Single-Photon Emission Computed CA tested in vivo was the Cr(III) complex of EDTA (EDTA = Tomography (SPECT) or Positron Emission Tomography (PET) ethylenediaminetetraacetic acid).3 Unfortunately, this candidate is definitely no use of harmful high-energy radiation. Moreover, suffered from a lack of long-term stability and has never been MRI often represents the only reliable diagnostic method for, e.g. used clinically. The first example of a modern MRI CA is cranial abnormalities or multiple sclerosis. The resolution reached considered to be the gadolinium(III) complex of DTPA (DTPA = 3 is close to 1 mm with contemporary MRI clinical scanners, diethylenetriaminepentaacetic acid) approved for clinical usage in and the resolution on the cellular level was demonstrated in 1988.4 a laboratory experimental setup. Consequently, the diagnostic From the physical point of view, there are two major fami- potential of MRI seems to be still enormous. In addition to lies of CAs classified according to the relaxation process they the assessment of anatomical changes, MRI can be utilized for predominantly accelerate, i.e. T 1-CAs (paramagnetic) and T 2- monitoring of organ functions. For instance, MRI has been used 1 CAs (superparamagnetic). Whereas T 1-CAs induce a positive to follow functions of the human brain on a real time-scale by a contrast, i.e. a 1H NMR signal of the affected tissue increases, method called functional-MRI or fMRI.2 compounds affecting the T 2 relaxation cause lowering of a local Physical principles of MRI rely on the monitoring of the dif- proton signal and, thus, they show a “negative enhancement” ferent distribution and properties of water in the examined tissue pattern.5 and also on a spatial variation of its proton longitudinal (T 1)and Besides this classification, all CAs can be divided (according to 1 transversal (T 2) magnetic relaxation times. Thus, an MRI scanner the site of action) into extracellular, organ-specific and blood pool is able to generate several types of images. A significant benefit of agents. Historically, the chemistry of the T 1-CAs has been explored MRI to medicinal diagnostics arises from a contrast produced by more extensively as the T 1 relaxation time of diamagnetic water local differences in healthy and pathologically changed parts of solutions is typically five-times longer than T 2 and, consequently the same tissue. In particular, T 1 and T 2 were proved to be rather 1 easier to shorten. From the chemical point of view, T 1-CAs are sensitive to biochemical conditions (such as water concentration, complexes of paramagnetic metal ions, such as Fe(III), Mn(II)or temperature, pH, salt or fat concentration etc.) of the tissue under Gd(III), with suitable organic ligands. study. On the other hand, T 2-CAs, developed slightly later, are conceptually microcrystalline iron oxide nanoparticles (MION), called also small superparamagnetic iron oxides (SPIO) or Department of Inorganic Chemistry, Faculty of Science, Universita Karlova 1,6 (Charles University), Hlavova 2030, 128 40, Prague 2, Czech Republic. ultrasmall superparamagnetic iron oxides (USPIO). In addition E-mail: [email protected]; Fax: +420-221951253; Tel: +420-221951259 to their effect on T 2, these agents also induce faster T 1-relaxation; This journal is © The Royal Society of Chemistry 2008 Dalton Trans., 2008, 3027–3047 | 3027 Petr Hermann started graduate Jan Kotek is a former student studies with Prof. Lukesˇ in 1988 Prof. I. Lukesˇ and Dr. P. Her- and graduated in 1993. He was a mann. He received his PhD de- postdoctoral fellow at University gree in 2004. He was then a post- of Massachusetts (Amherst) doctoral fellow in Leuven (Bel- with Prof. L. D. Quin (1993– gium) under the supervision of 1995). At his alma mater,he Prof. K. Binnemans. He has been became a lecturer (1993) and a lecturer in the department since docent (2004). His current re- 2000 and is a member of Prof. search is focused on synthesis Lukes’ˇ team involved mostly in and investigations of complex- the synthesis, potentiometry and ing ability of polyazamacrocy- X-ray studies of macrocyclic lig- cles with phosphorous acid pen- ands and their complexes. Petr Hermann Jan Kotek dant arms. Vojtechˇ Kub´ıcekˇ was born in Ivan Lukes’ˇ studies (PhD 1976) 1978. He obtained his PhD de- as well as his career are con- gree in inorganic chemistry in nected with Universita Karlova 2007. Now, he works in the group except stays in Orsted Insti- of Coordination and Bioinor- tute in Copenhagen (1984) and ganic Chemistry at Charles Uni- University of Massachusetts at versity in Prague. His scientific Amherst (1991–92). Through interest is focused on the synthe- the years his research inter- sis and coordination chemistry est has focused on coordination of organophosphorus compounds chemistry and also on phospho- and on the design of macrocyclic rus chemistry. At present, he is chelators for molecular imaging. concerned with lanthanide com- plexes and their biomedical ap- Vojtechˇ Kub´ıcekˇ Ivan Lukesˇ plication. nevertheless, they are mostly used as negative CAs. Basically, they complexes are written, according to the IUPAC nomenclature, in consist of nonstoichiometric Fe3O4/Fe2O3 cores of various sizes small letters. (from several nanometers to several tens of nanometers) covered by e.g. dextrans or polysiloxanes; hence, their final size reaches Structures of gadolinium(III)-based contrast agents several hundred nanometers. In practice, they are used as blood- pool and more recently as organ-specific CAs. As highlighted above, the T 1-CAs are mostly based on coordina- In clinical practice, more than 35% of MRI examinations tion compounds where the paramagnetic metal ion is wrapped in are performed with the use of CAs. The T 1-CAs based on a multidentate organic ligand. At present, the most widespread gadolinium(III) complexes are mostly applied; thus, in this paper, family of the T 1-CAs consists of complexes with the Gd(III) ion. we focus on them and, especially, on the coordination chemistry Although there are other candidates in the lanthanide series that that controls the properties of such CAs. Utilization of the iron have a high magnetic moment, the intrinsic relaxation time of oxide nanoparticles is rather limited, an estimated proportion is the electron-spin state of the cation has to be long enough for less than 10% of all CA administrations. efficient transfer of magnetic information to the bulk water. Thus, In this rapidly developing field, a number of reviews on different the prominent position of the Gd(III) ion relies not only in a high aspects of the chemistry of complexes associated with CAs magnetic moment (7.9 BM) given by seven unpaired f -electrons, 1,7,8 8 developments and usages have been published: monographs, but also in a totally symmetric electronic state ( S7/2 ground state), reviews of general interest,9–18 reviews on physical aspects,19 solid- which makes the electronic relaxation time much longer than for − − state structures,20,21 thermodynamic/kinetic stability,20–24 pro- other Ln(III) ions, 10 8–10 9 s.5 However, the main problem of totropic exchange,25 second-sphere effects,26 quantum chemi- the medical utilizations of heavy metal ions like the Gd(III)ion cal calculations,27 targeted/responsive CAs,28–31 macromolecular is a significant toxicity of their “free” (aqua-ion) form. Thus, for CAs32,33 or multimodal CAs.34 clinical use of gadolinium(III), it must be bound in a complex of To avoid any ambiguity, fully protonated free ligands (e.g.
Recommended publications
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Page 1 of 19 RSC Advances
    RSC Advances This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/advances Page 1 of 19 RSC Advances A greener approach toward gadolinium-based contrast agents Thais P. Gazzi, Luiz A. Basso, Diógenes S. Santos* and Pablo Machado* Instituto Nacional de Ciência e Tecnologia em Tuberculose, Centro de Pesquisas em Biologia Molecular e Funcional, Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, 90619-900, Porto Alegre, RS, Brazil Manuscript Accepted Advances RSC *Corresponding authors. Phone/Fax: +55 51 3320 3629 E-mail address: [email protected] (D.S. Santos); [email protected] (P. Machado) RSC Advances Page 2 of 19 Graphical Abstract Manuscript Abstract Gadolinium-based contrast agents are widely used to enhance the contrast of images in magnetic resonance imaging procedures.
    [Show full text]
  • New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology
    molecules Review New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology Anna Lucia Tornesello * ID , Luigi Buonaguro, Maria Lina Tornesello and Franco Maria Buonaguro Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori, IRCCS, Fondazione Pascale, 80131 Napoli, Italy; [email protected] (L.B.); [email protected] (M.L.T.); [email protected] (F.M.B.) * Correspondence: [email protected]; Tel.: +39-0825-1911-711 Received: 30 May 2017; Accepted: 25 July 2017; Published: 2 August 2017 Abstract: Many synthetic peptides have been developed for diagnosis and therapy of human cancers based on their ability to target specific receptors on cancer cell surface or to penetrate the cell membrane. Chemical modifications of amino acid chains have significantly improved the biological activity, the stability and efficacy of peptide analogues currently employed as anticancer drugs or as molecular imaging tracers. The stability of somatostatin, integrins and bombesin analogues in the human body have been significantly increased by cyclization and/or insertion of non-natural amino acids in the peptide sequences. Moreover, the overall pharmacokinetic properties of such analogues and others (including cholecystokinin, vasoactive intestinal peptide and neurotensin analogues) have been improved by PEGylation and glycosylation. Furthermore, conjugation of those peptide analogues to new linkers and bifunctional chelators (such as AAZTA, TETA, TRAP, NOPO etc.), produced radiolabeled moieties with increased half life and higher binding affinity to the cognate receptors. This review describes the most important and recent chemical modifications introduced in the amino acid sequences as well as linkers and new bifunctional chelators which have significantly improved the specificity and sensitivity of peptides used in oncologic diagnosis and therapy.
    [Show full text]
  • Assessment Report
    13 October 2016 EMA/734748/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report SomaKit TOC International non-proprietary name: edotreotide Procedure No. EMEA/H/C/004140/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ..................................................................................... 6 1.2. Steps taken for the assessment of the product ........................................................ 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition .......................................................................................... 8 2.1.2. Epidemiology .................................................................................................... 8 2.1.3. Biologic features ............................................................................................... 9 2.1.4. Clinical presentation .......................................................................................
    [Show full text]
  • Ga]Ga-DOTA-TOC: the First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
    pharmaceuticals Review [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging Ute Hennrich 1,* and Martina Benešová 2 1 Division of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany 2 Molecular Biology of Systemic Radiotherapy Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; [email protected] * Correspondence: [email protected] Received: 15 January 2020; Accepted: 1 March 2020; Published: 3 March 2020 Abstract: In the United States, [68Ga]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [68Ga]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide 68Ga with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response. Keywords: [68Ga]Ga-DOTA-TOC; positron emission tomography (PET); somatostatin receptor (SSTR); neuroendocrine tumors (NETs); theranostics 1. Introduction On 21 August 2019, [68Ga]Ga-DOTA-TOC was approved by the Food and Drug Administration (FDA) [1] for positron emission tomography (PET) imaging of somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors. Holder of the marketing authorization is the UIHC–PET Imaging Center (University of Iowa Health Care (UIHC)), in Iowa, USA. The ready-to-use 68Ga-labeled peptide was already approved in some European countries (Austria, Germany, and France) in 2016 (IASOtoc®, IASON GmbH, Graz, Austria) [2] and in 2018 (TOCscan®, ITM AG, München, Germany) [3].
    [Show full text]
  • Iaea Tecdoc Series
    IAEA-TECDOC-1863 IAEA-TECDOC-1863 IAEA TECDOC SERIES IAEA-TECDOC-1863 Gallium-68 Cyclotron Production International Atomic Energy Agency Vienna ISBN 978–92–0–100819–0 ISSN 1011–4289 @ GALLIUM-68 CYCLOTRON PRODUCTION The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GERMANY PALAU ALBANIA GHANA PANAMA ALGERIA GREECE PAPUA NEW GUINEA ANGOLA GRENADA PARAGUAY ANTIGUA AND BARBUDA GUATEMALA PERU ARGENTINA GUYANA PHILIPPINES ARMENIA HAITI POLAND AUSTRALIA HOLY SEE PORTUGAL AUSTRIA HONDURAS QATAR AZERBAIJAN HUNGARY REPUBLIC OF MOLDOVA BAHAMAS ICELAND ROMANIA BAHRAIN INDIA BANGLADESH INDONESIA RUSSIAN FEDERATION BARBADOS IRAN, ISLAMIC REPUBLIC OF RWANDA BELARUS IRAQ SAINT VINCENT AND BELGIUM IRELAND THE GRENADINES BELIZE ISRAEL SAN MARINO BENIN ITALY SAUDI ARABIA BOLIVIA, PLURINATIONAL JAMAICA SENEGAL STATE OF JAPAN SERBIA BOSNIA AND HERZEGOVINA JORDAN SEYCHELLES BOTSWANA KAZAKHSTAN SIERRA LEONE BRAZIL KENYA SINGAPORE BRUNEI DARUSSALAM KOREA, REPUBLIC OF SLOVAKIA BULGARIA KUWAIT SLOVENIA BURKINA FASO KYRGYZSTAN SOUTH AFRICA BURUNDI LAO PEOPLE’S DEMOCRATIC SPAIN CAMBODIA REPUBLIC SRI LANKA CAMEROON LATVIA SUDAN CANADA LEBANON SWEDEN CENTRAL AFRICAN LESOTHO SWITZERLAND REPUBLIC LIBERIA CHAD LIBYA SYRIAN ARAB REPUBLIC CHILE LIECHTENSTEIN TAJIKISTAN CHINA LITHUANIA THAILAND COLOMBIA LUXEMBOURG THE FORMER YUGOSLAV CONGO MADAGASCAR REPUBLIC OF MACEDONIA COSTA RICA MALAWI TOGO CÔTE D’IVOIRE MALAYSIA TRINIDAD AND TOBAGO CROATIA MALI TUNISIA CUBA MALTA TURKEY CYPRUS MARSHALL ISLANDS TURKMENISTAN CZECH REPUBLIC MAURITANIA
    [Show full text]
  • IAEA TECDOC SERIES Production of Emerging Radionuclides Towards Theranostic Applications: Copper-61, Scandium-43 and -44, and Yttrium-86
    IAEA-TECDOC-1955 IAEA-TECDOC-1955 IAEA TECDOC SERIES Production of Emerging Radionuclides towards Theranostic Applications: Copper-61, Scandium-43 and -44, and Yttrium-86 and Scandium-43 and -44, Copper-61, Applications: Theranostic towards Production of Emerging Radionuclides IAEA-TECDOC-1955 Production of Emerging Radionuclides towards Theranostic Applications: Copper-61, Scandium-43 and -44, and Yttrium-86 International Atomic Energy Agency Vienna @ PRODUCTION OF EMERGING RADIONUCLIDES TOWARDS THERANOSTIC APPLICATIONS: COPPER-61, SCANDIUM-43 AND -44, AND YTTRIUM-86 The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GEORGIA OMAN ALBANIA GERMANY PAKISTAN ALGERIA GHANA PALAU ANGOLA GREECE PANAMA ANTIGUA AND BARBUDA GRENADA PAPUA NEW GUINEA ARGENTINA GUATEMALA PARAGUAY ARMENIA GUYANA PERU AUSTRALIA HAITI PHILIPPINES AUSTRIA HOLY SEE POLAND AZERBAIJAN HONDURAS PORTUGAL BAHAMAS HUNGARY QATAR BAHRAIN ICELAND REPUBLIC OF MOLDOVA BANGLADESH INDIA ROMANIA BARBADOS INDONESIA RUSSIAN FEDERATION BELARUS IRAN, ISLAMIC REPUBLIC OF RWANDA BELGIUM IRAQ SAINT LUCIA BELIZE IRELAND BENIN ISRAEL SAINT VINCENT AND BOLIVIA, PLURINATIONAL ITALY THE GRENADINES STATE OF JAMAICA SAN MARINO BOSNIA AND HERZEGOVINA JAPAN SAUDI ARABIA BOTSWANA JORDAN SENEGAL BRAZIL KAZAKHSTAN SERBIA BRUNEI DARUSSALAM KENYA SEYCHELLES BULGARIA KOREA, REPUBLIC OF SIERRA LEONE BURKINA FASO KUWAIT SINGAPORE BURUNDI KYRGYZSTAN SLOVAKIA CAMBODIA LAO PEOPLE’S DEMOCRATIC SLOVENIA CAMEROON REPUBLIC SOUTH AFRICA CANADA LATVIA SPAIN CENTRAL AFRICAN LEBANON
    [Show full text]